{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:31:46Z","timestamp":1778657506077,"version":"3.51.4"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej16-0337","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T03:06:21Z","timestamp":1489806381000},"page":"507-513","source":"Crossref","is-referenced-by-count":6,"title":["Saline Infusion Test highly associated with the incidence of cardio- and cerebrovascular events in primary aldosteronism"],"prefix":"10.1507","volume":"64","author":[{"given":"Reiko","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. Conn JW (1966-1967) The evolution of primary aldosteronism: 1954-1967. <i>Harvey Lect<\/i> 62: 257-291."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, <i>et al<\/i>. (2006) Prev-alence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. <i>J Hum Hypertens<\/i> 20: 129-136.","DOI":"10.1038\/sj.jhh.1001948"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nishikawa T, Omura M (2000) Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. <i>Biomed Pharmacother<\/i> 54 Suppl 1: 83s-85s.","DOI":"10.1016\/S0753-3322(00)80019-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, <i>et al<\/i>. (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 93: 3266-3281.","DOI":"10.1210\/jc.2008-0104"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Catena C, Colussi G, Marzano L, Sechi LA (2012) Aldosterone and the heart: from basic research to clinical evidence. <i>Horm Metab Res<\/i> 44: 181-187.","DOI":"10.1055\/s-0031-1291318"},{"key":"6","unstructured":"6. Catena C, Colussi G, Brosolo G, Iogna-Prat L, Sechi LA (2012) Aldosterone and aldos-terone antagonists in cardiac disease: what is known, what is new. <i>Am J Cardiovasc Dis<\/i> 2: 50-57."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, <i>et al<\/i>. (2013) Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. <i>J Clin Endocrinol Metab<\/i> 98: 4826-4833.","DOI":"10.1210\/jc.2013-2805"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, <i>et al<\/i>. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. <i>J Am Coll Car-diol<\/i> 45: 1243-1248.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T (1995) Vascular compli-cations in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. <i>J Endo-crinol Invest<\/i> 18: 370-373.","DOI":"10.1007\/BF03347840"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, <i>et al<\/i>. (2008) Cardio-vascular outcomes in patients with primary aldosteronism after treatment. <i>Arch Intern Med<\/i> 168: 80-85.","DOI":"10.1001\/archinternmed.2007.33"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Savard S, Amar L, Plouin PF, Steichen O (2013) Cardiovascular complications associ-ated with primary aldosteronism: a controlled cross-sectional study. <i>Hypertension<\/i> 62: 331-336.","DOI":"10.1161\/HYPERTENSIONAHA.113.01060"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, <i>et al<\/i>. (2006) PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. <i>Hypertension<\/i> 48: 232-238.","DOI":"10.1161\/01.HYP.0000230444.01215.6a"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, <i>et al<\/i>. (2006) Long-term renal outcomes in patients with primary aldosteronism. <i>JAMA<\/i> 295: 2638-2645.","DOI":"10.1001\/jama.295.22.2638"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanase-Nakao K, Naruse M, Nanba K, Tsuiki M, Tagami T, <i>et al<\/i>. (2014) Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with pri-mary aldosteronism. <i>Clin Endocrinol (Oxf) <\/i>81: 665-670.","DOI":"10.1111\/cen.12497"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, <i>et al<\/i>. (2011) Guide-lines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. <i>Endocr J<\/i> 58: 711-721.","DOI":"10.1507\/endocrj.EJ11-0133"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD (2012) Factors affecting the aldosterone\/renin ratio. <i>Horm Metab Res<\/i> 44: 170-176.","DOI":"10.1055\/s-0031-1295460"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, <i>et al<\/i>. (1984) Further evaluation of saline infusion for the diagnosis of primary aldosteronism. <i>Hypertension<\/i> 6: 717-723.","DOI":"10.1161\/01.HYP.6.5.717"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, <i>et al<\/i>. (2007) PAPY Study Investigators; Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. <i>J Hypertens<\/i> 25: 1433-1442.","DOI":"10.1097\/HJH.0b013e328126856e"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K (2001) Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. <i>J Clin Endocrinol Metab<\/i> 86: 4292-4298.","DOI":"10.1210\/jcem.86.9.7867"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Castro OL, Yu X, Kem DC (2002) Diagnostic value of the post-captopril test in primary aldosteronism. <i>Hypertension<\/i> 39: 935-938.","DOI":"10.1161\/01.HYP.0000014324.68506.CA"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Weigel M, Riester A, Hanslik G, Lang K, Willenberg HS, <i>et al<\/i>. (2015) Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. <i>Eur J Endocrinol<\/i> 172: 443-450.","DOI":"10.1530\/EJE-14-1013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, <i>et al<\/i>. (2002) A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. <i>J Hum Hypertens<\/i> 16: 97-103.","DOI":"10.1038\/sj.jhh.1001307"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, <i>et al<\/i>. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. <i>Am<\/i> <i>J Physiol Heart Circ Physiol <\/i>283: H1802-1810.","DOI":"10.1152\/ajpheart.01096.2001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, <i>et al<\/i>. (2002) Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading.<i> Hypertension<\/i> 39: 614-618.","DOI":"10.1161\/hyp.39.2.614"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr (1998) Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. <i>Hypertension <\/i>31: 451-458.","DOI":"10.1161\/01.HYP.31.1.451"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML,<i> et al<\/i>. (2003) Aldoste-rone\/salt induces renal inflammation and fibrosis in hypertensive rats. <i>Kidney Int <\/i>63: 1791-1800.","DOI":"10.1046\/j.1523-1755.2003.00929.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, <i>et al<\/i>. (2011) Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Re-sults of a Case-Control Study. <i>J Clin Endocrinol Metab<\/i> 96: 2813-2820.","DOI":"10.1210\/jc.2011-0354"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Komukai K, Mochizuki S, Yoshimura M (2010) Gender and the ren-in-angiotensin-aldosterone system. <i>Fundam Clin Pharmacol<\/i> 24: 687-698.","DOI":"10.1111\/j.1472-8206.2010.00854.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nakama C, Kamide K, Kawai T, Hongyo K, Ito N, <i>et al<\/i>. (2014) The influence of aging on the diagnosis of primary aldosteronism. <i>Hypertens Res<\/i> 37: 1062-1067.","DOI":"10.1038\/hr.2014.129"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/5\/64_EJ16-0337\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T22:22:55Z","timestamp":1568931775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/5\/64_EJ16-0337\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej16-0337","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}